首页> 美国卫生研究院文献>Neuro-Oncology >DRES-04. DEVELOPMENT OF A CRISPR-CAS9D10A TARGETABLE HIGH-COMPLEXITY SINGLE-CELL BARCODING APPROACH FOR ISOLATION OF TREATMENT RESISTANT SUBCLONES FROM HETEROGENOUS MALIGNANT GLIOMAS
【2h】

DRES-04. DEVELOPMENT OF A CRISPR-CAS9D10A TARGETABLE HIGH-COMPLEXITY SINGLE-CELL BARCODING APPROACH FOR ISOLATION OF TREATMENT RESISTANT SUBCLONES FROM HETEROGENOUS MALIGNANT GLIOMAS

机译:DRES-04。 CRISPR-CAS9D10A可靶向高复杂性单细胞编排方法从异质恶性胶质瘤中分离抗药性子代的方法的开发

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Malignant gliomas are composed of heterogeneous cell populations and the clonal evolution of these cells is one of the key reasons for treatment resistance and tumor recurrence. A fundamental challenge in studying clonal evolution in these tumors is the difficulty in isolating the phenotype-associated (e.g. treatment resistant) sub-populations from the heterogeneous population. We developed an approach to individually barcode and isolate specific cell subpopulations using a CRISPR (clustered, regularly interspaced, short palindromic repeat)-Cas9D10A targetable, single-cell barcoding library with a complexity of 36 million unique barcodes. This approach enabled us to uniquely barcode > 1 million cells, identify enriching barcoded sub-populations following treatment and then isolate the resistant subpopulation using the subpopulation-specific barcode. Each barcode sequence carrying two guide RNAs so that CRISPR-Cas9D10A targeting can lead to “switching” (i.e. frameshift) of an EGFP (Enhanced Green Fluorescent Protein) reporter. Thus, targeted cells lose their EGFP signal and can be specifically isolated by cell sorting. Proof of principle studies showed that specific barcoding cells could be efficiently targeted to turn off EGFP and subpopulations isolated. Subsequent large-scale implementation of this approach has been performed to isolate resistant subpopulations following radiation and temozolomide. Our approach will lead to identification of the both pre-existing and acquired specific somatic genetic or epigenetic changes driving treatment resistance in patients with malignant gliomas.
机译:恶性神经胶质瘤由异种细胞群体组成,这些细胞的克隆进化是治疗耐药性和肿瘤复发的关键原因之一。研究这些肿瘤的克隆进化过程中的一个基本挑战是难以从异质群体中分离出与表型相关的(例如治疗耐药性)亚群。我们开发了一种使用CRISPR(聚簇的,规则间隔的,短回文重复序列)-Cas9D10A可靶向的单细胞条形码库来单独条形码和分离特定细胞亚群的方法,其复杂性为3600万个独特条形码。这种方法使我们能够唯一地条形码> 100万个细胞,在处理后识别富集的条形码亚群,然后使用特定于亚群的条形码分离出抗性亚群。每个条形码序列均带有两个引导RNA,因此CRISPR-Cas9D10A靶向可导致EGFP(增强型绿色荧光蛋白)报告基因的“转换”(即移码)。因此,靶向细胞会丢失其EGFP信号,可以通过细胞分选特异性分离。原理研究证明,特定的条形码细胞可以有效地靶向关闭EGFP并分离出亚群。随后进行了该方法的大规模实施,以分离辐射和替莫唑胺后的耐药亚群。我们的方法将导致对恶性神经胶质瘤患者驱动治疗耐药性的既有和已获得的特定体细胞遗传或表观遗传学变化进行鉴定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号